Загрузка...
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small cell lung cancer (NSCLC). However, EGFR T790M mutation leads to resistance to most clinically available EGFR TKIs. Third-generation EGFR TKIs against the T790M mutation hav...
Сохранить в:
Опубликовано в: : | J Hematol Oncol |
---|---|
Главные авторы: | , , |
Формат: | Artigo |
Язык: | Inglês |
Опубликовано: |
BioMed Central
2016
|
Предметы: | |
Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4830020/ https://ncbi.nlm.nih.gov/pubmed/27071706 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0268-z |
Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|